We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 28, 2019

Ibrutinib and R-CHOP in Non–Germinal Center B-Cell DLBCL

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
J. Clin. Oncol 2019 Mar 22;[EPub Ahead of Print], A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, D Belada, O Samoilova, C Suh, S Leppä, S Rai, M Turgut, W Jurczak, MC Cheung, R Gurion, SP Yeh, A Lopez-Hernandez, U Dührsen, C Thieblemont, CS Chiattone, S Balasubramanian, J Carey, G Liu, SM Shreeve, S Sun, SH Zhuang, J Vermeulen, LM Staudt, W Wilson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading